Neurosteroid mPR Agonists for GABAergic Inhibition in CNS Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods and therapeutic agents are inadequate for effectively modulating GABAergic inhibition to treat CNS-related disorders such as psychiatric and neurological conditions associated with impaired neuronal excitability, including rapid mood changes, anxiety, stress response, and epilepsy.
Innovation Solution
The use of membrane progesterone receptor (mPR) agonists, which can be natural or synthetic neuroactive steroids, to modulate GABAergic inhibition through allosteric and metabotropic mechanisms, increasing the expression and phosphorylation of GABA receptor subunits, thereby enhancing GABAergic inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents are used to treat CNS-related disorders, then treatment is provided, but they are inadequate for effectively modulating GABAergic inhibition
Solution Approach 1:
The patent changes the chemical structure parameters of neurosteroid compounds to create novel mPR agonists with improved GABAergic modulation efficacy. By modifying the steroid backbone and functional groups, the invention achieves better binding affinity and selectivity for membrane progesterone receptors, thereby effectively treating CNS-related disorders that were resistant to conventional agents.
2Reliability
If membrane progesterone receptor agonists are used to modulate GABAergic inhibition, then GABAergic inhibition is enhanced, but the mechanism involves complex allosteric and metabotropic pathways
Solution Approach 1:
The patent introduces membrane progesterone receptors as intermediary molecules that mediate the interaction between neurosteroid agonists and GABAergic inhibition. These mPRs serve as signaling intermediaries that translate ligand binding into downstream effects on GABA receptor function, providing a controlled and specific mechanism for enhancing inhibition while managing pathway complexity.
3Reliability
If neuroactive steroids are administered to increase GABA receptor expression and phosphorylation, then treatment efficacy is improved, but specific compounds like progesterone, 5α-DHP, allopregnanolone, and testosterone are excluded from the invention
Solution Approach 1:
The patent applies local quality by specifying particular structural features and pharmacological properties that the neurosteroid compounds must possess. Rather than excluding all known steroids, the invention identifies specific structural modifications and binding characteristics that confer superior efficacy, allowing selective optimization of compound properties for enhanced therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances GABAergic inhibition by increasing the membrane-associated amount of GABA receptors and their phosphorylation, leading to improved treatment of CNS-related disorders by reducing brain excitability and alleviating symptoms.
Implementation Method 1
The modulation effect of these candidate GABAergic inhibitors can be allosteric, metabotropic, or both
Implementation Method 2
The modulation effect of these candidate GABAergic inhibitors can be allosteric, metabotropic, or both
Implementation Method 3
increasing the expression and phosphorylation of GABA receptor subunits
Implementation Method 4
Activation of GABA receptors by GABA causes hyperpolarization of neuronal membranes and a resultant inhibition of neurotransmitter release, thereby reducing brain excitability
Data Source
AI summary
Provided herein are methods, therapeutic agents and composition for treating a CNS-related disorder.